Background Mild cognitive impairment (MCI), an age-related predementia cognitive
disorder, affects the quality of life in the elderly. Currently, there is no effective treatment for …

Background: Cognitive impairment is a major problem in elderly, affecting quality of life. Pre-
clinical studies show that MMFS-01, a synapse density enhancer, is effective at reversing …

Background Alzheimer's Disease (AD) is a synaptic dysfunction disease; synaptic loss is the
best predictor of cognitive decline. Therefore, a compound that can increase synaptic …

Increased knowledge of the biology of synaptic function has led to the development of novel
cognitive-enhancing therapeutic strategies with the potential for increased efficacy and …

Background An estimated 60% of older adults with subjective cognitive decline (SCD)
progress to Alzheimer's dementia over a 15-year period (Reisberg et al., 2008). Early …

Background The combined effects of the aging of the population (caused by the shift of the
baby boomer generation into dementia) and significant increase in life expectancy has …

Background CHF5074 is a new microglial modulator that has been shown to prevent brain
plaque deposition and attenuate memory deficits in transgenic mouse models of AD. In man …

Background Mild cognitive impairment (MCI) may represent a preclinical stage of
Alzheimer's disease. Early treatment of MCI may delay the development of dementia …

Background The identification of cognitive impairment raises the opportunity to act with the
aim of preventing dementia. One potential measure is memory training. Methods A …

Background Drug development in age-related neurodegenerative disorders (Alzheimer's
Disease) has increasingly focused on earlier disease stages, before overt dementia …